Qulipta (atogepant tablets – AbbVie) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has ≥ 4 migraine headache days per month prior to initiating a migraine-preventive medication
• If the patient is currently taking Qulipta, patient has had a significant clinical benefit from the medication as determined by the prescriber (e.g., reduction in overall or severe migraine days per month)

Reauthorization criteria

• Patient continues to have significant clinical benefit from Qulipta as determined by the prescriber (e.g., reduction in overall or severe migraine days per month)

Approval duration

1 year